Welcome to our dedicated page for Regulus Therapeu SEC filings (Ticker: RGLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regulus Therapeutics Inc. filings document the public-company record of a biopharmaceutical issuer focused on microRNA-targeted medicines and its completed transition out of Nasdaq-listed reporting status. Recent filings include an 8-K reporting completion of an acquisition transaction involving Novartis AG, a Form 25 covering removal of Regulus common stock from Nasdaq listing and registration, and a Form 15 covering termination or suspension of Exchange Act reporting duties for its common stock.
The filing record also identifies the RGLS common stock class, capital-structure status, material-event reporting, exchange-listing matters and deregistration mechanics. These disclosures frame Regulus as a former reporting issuer whose regulatory documents now primarily record corporate-status changes after its biopharmaceutical development activity.
Regulus Therapeutics Inc. (RGLS): Schedule 13G/A disclosure summarizing Point72 filings. Point72 Asset Management, Point72 Capital Advisors Inc. and Steven A. Cohen report beneficial ownership of 241,157 shares, representing 0.3% of the outstanding common stock on a diluted basis. The filing states these shares include shares issuable upon exercise of warrants and that Point72 entities hold shared voting and dispositive power over 241,157 shares with no sole voting or dispositive power. The ownership percentage is calculated using a total of 69,475,246 shares outstanding, which includes the 241,157 warrant shares.
Regulus Therapeutics Inc. is the subject of a Schedule 13G/A filed by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin reporting that none of the reporting persons beneficially own any shares of Regulus common stock. The filing lists 0 shares and 0.00% ownership, with beneficial ownership calculated using an issuer share count of 69,234,089 common shares outstanding.
The reporting persons state the securities were not acquired to influence control of the issuer and that the filing is made on behalf of each undersigned. This disclosure indicates the filers currently hold no economic or voting interest in Regulus and do not represent a change in ownership or control.